期刊
ESC HEART FAILURE
卷 8, 期 4, 页码 2580-2590出版社
WILEY PERIODICALS, INC
DOI: 10.1002/ehf2.13406
关键词
Heart failure; Diabetes; SGLT2 inhibitors; P-31-MRS; Trial design; Empagliflozin
资金
- Boehringer Ingelheim
- Oxford British Heart Foundation (BHF) Centre of Research Excellence
- Oxford National Institute for Health Research (NIHR) Biomedical Research Centre (BRC)
- Sir Henry Dale Fellowship from the Wellcome Trust [098436/Z/12/B]
- Royal Society [221805/Z/20/Z]
- Slovak Grant Agency VEGA [2/0001/17]
- Slovak Grant Agency APVV [15-0029]
- Wellcome Trust [221805/Z/20/Z] Funding Source: Wellcome Trust
Empagliflozin has shown significant benefits in reducing HF hospitalization and cardiovascular mortality. The EMPA-VISION trial aims to study the effects of empagliflozin on cardiac energy metabolism using MRS and CMR, shedding light on its mechanistic action in HF patients.
Aims Despite substantial improvements over the last three decades, heart failure (HF) remains associated with a poor prognosis. The sodium-glucose co-transporter-2 inhibitor empagliflozin demonstrated significant reductions of HF hospitalization in patients with HF independent of the presence or absence of type 2 diabetes mellitus in the EMPEROR-Reduced trial and cardiovascular mortality in the EMPA-REG OUTCOME trial. To further elucidate the mechanisms behind these positive outcomes, this study aims to determine the effects of empagliflozin treatment on cardiac energy metabolism and physiology using magnetic resonance spectroscopy (MRS) and cardiovascular magnetic resonance (CMR). Methods and results The EMPA-VISION trial is a double-blind, randomized, placebo-controlled, mechanistic study. A maximum of 86 patients with HF with reduced ejection fraction (n = 43, Cohort A) or preserved ejection fraction (n = 43, Cohort B), with or without type 2 diabetes mellitus, will be enrolled. Participants will be randomized 1:1 to receive either 10 mg of empagliflozin or placebo for 12 weeks. Eligible patients will undergo cardiovascular magnetic resonance, resting and dobutamine stress MRS, echocardiograms, cardiopulmonary exercise tests, serum metabolomics, and quality of life questionnaires at baseline and after 12 weeks. The primary endpoint will be the change in resting phosphocreatine-to-adenosine triphosphate ratio, as measured by (31)Phosphorus-MRS. Conclusions EMPA-VISION is the first clinical trial assessing the effects of empagliflozin treatment on cardiac energy metabolism in human subjects in vivo. The results will shed light on the mechanistic action of empagliflozin in patients with HF and help to explain the results of the safety and efficacy outcome trials (EMPEROR-Reduced and EMPEROR-Preserved).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据